Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement

BACKGROUND: Metabolomic analyses from our group and others have shown that tumors treated with glutamine antagonists (GA) exhibit robust accumulation of formylglycinamide ribonucleotide (FGAR), an intermediate in the de novo purine synthesis pathway. The increase in FGAR is attributed to the inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Alt, Jesse, Gori, Sadakatali S., Lemberg, Kathryn M., Pal, Arindom, Veeravalli, Vijayabhaskar, Wu, Ying, Aguilar, Joanna M.H., Dash, Ranjeet P., Tenora, Lukáš, Majer, Pavel, Sun, Qi, Slusher, Barbara S., Rais, Rana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684803/
https://www.ncbi.nlm.nih.gov/pubmed/34488583
http://dx.doi.org/10.2174/1389200222666210831125041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684803/
https://www.ncbi.nlm.nih.gov/pubmed/34488583
http://dx.doi.org/10.2174/1389200222666210831125041

Ejemplares similares